Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

This study is currently recruiting participants.

Verified February 2011 by University of Pittsburgh

First Received on September 13, 2005. Last Updated on February 17, 2011 History of Changes

Sponsor:	University of Pittsburgh
Collaborator:	Celgene Corporation
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00177814

Purpose

The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.

Condition
Gram-negative Bacterial Infections

Study Type:	Observational
Study Design:	Time Perspective: Retrospective
Official Title:	Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics Bacterial Infections

Drug Information available for: Piperacillin sodium Piperacillin

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Estimated Enrollment:	1000
Study Start Date:	September 2005
Estimated Study Completion Date:	December 2015

Detailed Description:

The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients treated with piperacillin/tazobactam and or piperacillin

Criteria

Inclusion Criteria:

Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177814

Contacts

Contact: David Paterson, MD	412-648-6401	patersond@dom.pitt.edu
Contact: Diana Pakstis, RN, BSN	412-648-6401	pakstisdl@dom.pitt.edu

Locations

United States, Pennsylvania
University of Pittsburgh Medical Center	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: David Paterson, MD 412-648-6401 patersond@dom.pitt.edu
Contact: Diana Pakstis, RN, BSN 412-648-6401 pakstisdl@dom.pitt.edu
Principal Investigator: David Paterson, MD

Sponsors and Collaborators

University of Pittsburgh

Celgene Corporation

Investigators

Principal Investigator:

David Paterson, MD

University of Pittsburgh

More Information

No publications provided

Responsible Party:	David Paterson, MD, UPMC
ClinicalTrials.gov Identifier:	NCT00177814 History of Changes
Other Study ID Numbers:	IRB # 0508074
Study First Received:	September 13, 2005
Last Updated:	February 17, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

pipercillin
gram negative bacteria infections

Additional relevant MeSH terms:

Bacterial Infections
Gram-Negative Bacterial Infections
Anti-Bacterial Agents
Piperacillin

Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2012